Abingworth raises $582 million for new Clinical Co-Development Fund – Over $1 billion raised in 2021 for two fundsWritten by: Asante Capital | Date: 10 May 2021
Asante Capital are pleased to announce the final closing of Abingworth’s new Clinical Co-Development Fund at $582 million. Abingworth Clinical Co-Development Fund 2 (ACCD 2) was significantly oversubscribed, exceeding its target of $350 million and closing at its hard cap. Alongside the recent $465 million Abingworth Bioventures (ABV 8) flagship fund, Abingworth has raised over $1 billion to invest in life science companies in the US, UK and Continental Europe developing innovative therapeutics with potential to significantly improve human health.
Asante Capital Group acted as global placement advisor for the fundraise.